mTOR Regulation Antibody Sampler Kit 9864T from Cell Signaling Technology

Product Specs
ItemmTOR Regulation Antibody Sampler Kit
CompanyCell Signaling Technology
Price $558.00 Inquire
Catalog Number9864T
Quantity1 Kit
TargetmTOR;mTOR (Ser2448) phosphate;Raptor (Ser792) phosphate;RagC;PRAS40 (Thr246) phosphate;PRAS40
NCBI Full Gene NameAKT1 substrate 1, Ras related GTP binding C, regulatory associated protein of MTOR complex 1, mechanistic target of rapamycin kinase
Research AreaPI3K / Akt Signaling
NCBI Gene AliasesRAGC, RAFT1, PRAS40, GTR2, SKS, Lobe, TIB929, FRAP1, FRAP2, KOG1, RAPT1, FRAP, Mip1

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

(1) Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphomaBlood AdvancesSeptember 22, 2020Neeraj Jain et al.with the following specific primary antibodies: anti-BTK (D3H5), anti-mTOR substrate/pathway (9862, 9864), anti-PI3kinases (9655), anti-pAKT (4060), anti-AKT (9272), anti-caspases (9929), and anti-inhibitor

(2) PPP2R2D, a regulatory subunit of protein phosphataseï¿½2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activationInternational Journal of OncologyMarch 20, 2018Shijun Yu, Li Li, Qiong Wu, Ning Dou, Yandong Li, Yong Gao(1:500; cat. no. 2038), mTOR (1:500; cat. no. 2983), phosphorylated (p)-mTOR (Ser2448) (1:500; cat. no. 9864), protein kinase B (Akt; 1:1,000; cat. no. 9272), p-Akt (1:500; cat. no. 4051), extracellular signal-regulated

(3) Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signalingOncotargetDecember 27, 2016Dou N, Yu S, Ye X, Yang D, Li Y, Gao Y.(1:1000, Proteintech, #14485).mTOR (7C10), Phospho-mTOR (Ser2448) (1:1000, Cell Signaling Technology, #9864), phospho-p70S6 Kinase(Thr389) (1:1000, Cell Signaling Technology, #9234),Phospho-S6 Ribosomal Protein

(4) Randomized controlled trial of an early discharge rehabilitation service: the Belfast Community Stroke TrialStrokeJanuary 1, 2004Michael Donnelly, Michael Power, Mary Russell, Ken Fullertonon each rehabilitation group. Mean cost of inpatient care for the CST group was lower (£7831 versus £9864; P⫽0.737) (Table 3). Community-based services also cost more for the HR group due to the relatively higher

mTOR Regulation Antibody Sampler Kit from Cell Signaling Technology